Sweden · Delayed Price · Currency is SEK Biovica International AB Statistics
Total Valuation
STO:BIOVIC.B has a market cap or net worth of SEK 92.24 million. The enterprise value is 46.68 million.
| Market Cap | 92.24M |
| Enterprise Value | 46.68M |
Important Dates
The last earnings date was Thursday, September 10, 2026.
| Earnings Date | Sep 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:BIOVIC.B has 291.91 million shares outstanding. The number of shares has increased by 195.13% in one year.
| Current Share Class | 277.49M |
| Shares Outstanding | 291.91M |
| Shares Change (YoY) | +195.13% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 15.03% |
| Owned by Institutions (%) | 17.31% |
| Float | 166.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.18 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.06 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -247.55 |
Financial Efficiency
Return on equity (ROE) is -156.59% and return on invested capital (ROIC) is -87.48%.
| Return on Equity (ROE) | -156.59% |
| Return on Assets (ROA) | -60.88% |
| Return on Invested Capital (ROIC) | -87.48% |
| Return on Capital Employed (ROCE) | -101.58% |
| Weighted Average Cost of Capital (WACC) | 10.16% |
| Revenue Per Employee | 622,208 |
| Profits Per Employee | -3.01M |
| Employee Count | 24 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.26 |
Taxes
In the past 12 months, STO:BIOVIC.B has paid 1.57 million in taxes.
| Income Tax | 1.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.87% in the last 52 weeks. The beta is 1.15, so STO:BIOVIC.B's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -48.87% |
| 50-Day Moving Average | 0.45 |
| 200-Day Moving Average | 0.40 |
| Relative Strength Index (RSI) | 27.86 |
| Average Volume (20 Days) | 1,007,412 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:BIOVIC.B had revenue of SEK 14.93 million and -72.23 million in losses. Loss per share was -0.26.
| Revenue | 14.93M |
| Gross Profit | 14.47M |
| Operating Income | -71.54M |
| Pretax Income | -70.66M |
| Net Income | -72.23M |
| EBITDA | -70.93M |
| EBIT | -71.54M |
| Loss Per Share | -0.26 |
Balance Sheet
The company has 51.59 million in cash and 6.02 million in debt, with a net cash position of 45.57 million or 0.16 per share.
| Cash & Cash Equivalents | 51.59M |
| Total Debt | 6.02M |
| Net Cash | 45.57M |
| Net Cash Per Share | 0.16 |
| Equity (Book Value) | 66.57M |
| Book Value Per Share | 0.23 |
| Working Capital | 40.43M |
Cash Flow
In the last 12 months, operating cash flow was -61.71 million and capital expenditures -2.33 million, giving a free cash flow of -64.04 million.
| Operating Cash Flow | -61.71M |
| Capital Expenditures | -2.33M |
| Depreciation & Amortization | 616,000 |
| Net Borrowing | -12.94M |
| Free Cash Flow | -64.04M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | 96.87% |
| Operating Margin | -479.08% |
| Pretax Margin | -473.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
STO:BIOVIC.B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -195.13% |
| Shareholder Yield | -195.13% |
| Earnings Yield | -78.30% |
| FCF Yield | -69.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
STO:BIOVIC.B has an Altman Z-Score of -8.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.44 |
| Piotroski F-Score | 4 |